163 related articles for article (PubMed ID: 20102688)
1. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.
Chekmasova AA; Brentjens RJ
Discov Med; 2010 Jan; 9(44):62-70. PubMed ID: 20102688
[TBL] [Abstract][Full Text] [Related]
2. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
Chekmasova AA; Rao TD; Nikhamin Y; Park KJ; Levine DA; Spriggs DR; Brentjens RJ
Clin Cancer Res; 2010 Jul; 16(14):3594-606. PubMed ID: 20628030
[TBL] [Abstract][Full Text] [Related]
3. Prospects and challenges of CAR-T in the treatment of ovarian cancer.
Chen B; Liu J
Int Immunopharmacol; 2024 May; 133():112112. PubMed ID: 38640714
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
5. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
[TBL] [Abstract][Full Text] [Related]
6. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
[TBL] [Abstract][Full Text] [Related]
8. Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
Guerra C; Kalaitsidou M; Kueberuwa G; Hawkins R; Edmondson R
Cancer Treat Rev; 2023 Dec; 121():102632. PubMed ID: 37837788
[TBL] [Abstract][Full Text] [Related]
9. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
11. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
Dobrzanski MJ; Rewers-Felkins KA; Quinlin IS; Samad KA; Phillips CA; Robinson W; Dobrzanski DJ; Wright SE
Clin Immunol; 2009 Dec; 133(3):333-52. PubMed ID: 19762283
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
Nesbeth YC; Martinez DG; Toraya S; Scarlett UK; Cubillos-Ruiz JR; Rutkowski MR; Conejo-Garcia JR
J Immunol; 2010 May; 184(10):5654-62. PubMed ID: 20400704
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin.
Parente-Pereira AC; Whilding LM; Brewig N; van der Stegen SJ; Davies DM; Wilkie S; van Schalkwyk MC; Ghaem-Maghami S; Maher J
J Immunol; 2013 Sep; 191(5):2437-45. PubMed ID: 23898037
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
17. L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
Hong H; Brown CE; Ostberg JR; Priceman SJ; Chang WC; Weng L; Lin P; Wakabayashi MT; Jensen MC; Forman SJ
PLoS One; 2016; 11(1):e0146885. PubMed ID: 26761817
[TBL] [Abstract][Full Text] [Related]
18. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.
Nesbeth Y; Scarlett U; Cubillos-Ruiz J; Martinez D; Engle X; Turk MJ; Conejo-Garcia JR
Cancer Res; 2009 Aug; 69(15):6331-8. PubMed ID: 19602595
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
[TBL] [Abstract][Full Text] [Related]
20. Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.
Cheng H; Ma R; Wang S; Wang Y; Li Y; Tang Z; Dou S; Wang Y; Zhu H; Ye X; Zhang T; Zhang Y; Li S; Zhao Y; Li Y; Cui H; Chang X
Front Immunol; 2021; 12():707468. PubMed ID: 34408750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]